p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer

British Journal of Cancer

Volumn 82, Issue 1, 2000, Pages 136-141

  Phillips, H A ^a   Howard, G C W ^a   Miller, W R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Bladder cancer; Bladder washings; Mutations; p53

Indexed keywords

PROTEIN P53;

ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0033988453     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0890     Document Type: Article

References (22)

1. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B and Kaye SB (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Br J Cancer 55: 678-684
2. Esrig D, Spruck CH, Nichols PW, Chaiwaun B, Steven K, Groshen S, Chen S-C, Skinner DG, Jones PA and Cote R (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumour grade and stage in bladder cancer. Am J Pathol 143: 1389-1397
3. Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA and Summerhayes IC (1995) Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 87: 129-133
4. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T and Terada M (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52: 1393-1398
5. Hermansen DK, Reuter VE, Whitmore WF, Fair WR and Melamed MR (1988) Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). J Urol 140: 1394-1396
6. Levesque P, Ramchurren N, Saini K, Joyce A, Libertino J and Summerhayes IC (1993) Screening of human bladder tumours and urine sediment for the presence of H-ras mutations. Int J Cancer 55: 785-790
7. Maier U, Simak R and Neuhold N (1995) The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 48: 314-317
8. Mao L, Schoenberg M, Scicchitano M, Erozan YS, Merlo A, Schwab D and Sidransky D (1996) Molecular detection of primary bladder cancer by microsatellite analysis. Science 271: 659-662
9. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708
10. Orita M, Suzuki Y, Sekiya T and Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879
11. Prosser J, Thompson AM, Granston G and Evans HJ (1990) Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 5: 1573-1579
12. Phillips HA, Burns D, Prosser J, Howard GCW and Miller WR (1996) The sensitivity of single-stranded conformational polymorphism in mutation detection in a mixed cell population. Br J Cancer 73: 45
13. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P and Vogelstein B (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709
14. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC and Vogelstein B (1992) Clonal origin of bladder cancer. N Engl J Med 326: 737-740
15. Sjögren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173-182
16. Smith TA, Whelan J and Parry PJ (1992) Detection of single-base mutations in a mixed population of cells: a comparison of SSCP and direct sequencing. Genet Anal Tech Applicat 9: 143-145
17. Steiner G, Schoenberg MP, Linn JF, Mao L and Sidransky D (1997) Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 3: 621-624
18. Vet JA, Witjes JA, Marras SAE, Hessels D, van der Poel HG, Debruyne FMJ and Schalken JA (1996) Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. Clin Cancer Res 2: 1055-1061
19. Walther PJ (1992) The role of flow cytometry in the management of bladder cancer. Hematol Oncol Clin North Am 6: 81-98
20. Winship PR (1989) An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide. Nucleic Acids Res 17: 1266
21. Wu JK, Ye Z and Darras BT (1993) Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumours with mixed cell populations. Am J Hum Genet 52: 1273-1275
22. Xu X, Stower MJ, Reid IN, Garner RC and Burns PA (1996) Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. Clin Cancer Res 2: 1795-1800